Drawing new conclusions about Parkinson's disease through research.
Statement from the Chairs – August, 2010

We are a young department, and it sometimes seems the only tradition we have developed is adaption to change. We faced-down the largest reductions in state education monies of any state in the nation, and emerged more organized, with a larger national reputation and ready for the future. We were not trapped by the downward projections of others.

“Sometimes we stare so long at a door that is closing that we see too late the one that is open.” – Alexander Graham Bell

Through everyone’s hard work, funding has been secured and we are in the midst of renovating an entire floor in the Clinical Sciences Building to promote creative interactions amongst clinicians, neuro-imaging and clinical researchers. These renovations are proceeding in two phases, both to be completed in Fall, 2011. Special thanks to many of our clinical faculty for believing in this project and undergoing the inconvenience of temporary dislocation. As well, we are close to securing funding to renovate Harborview Tower and creating a departmental facility that will house out-patient clinical research activities in stroke, Alzheimer’s disease, movement disorders, the Aging Institute, epidemiology and the Translational Research Unit. With a little luck, this should be completed by Spring 2012.

Equally exciting, between summer and fall of 2011, we will begin to move largely new recruits into wet-bench research space in the newly completed Biomedical Engineering and Drug Discovery Bldgs. We have ~9000 sq ft of space to occupy, and are chartering a 3-year recruitment plan to bring about growth in our translational research enterprises, as well as bring cutting edge research technologies to campus. Please welcome a lot of new faces appearing for interviews beginning in 2011!

The arrival of new space and the unprecedented departmental growth in research and clinical activity are architects of change.

“Be the change you want to see in the world” – Mahatma Gandhi

We have all done our best to maximize opportunities and retain the tripartite fundamentals of patient care, education and creating new knowledge through research. However, given the magnitude of potential energy inherent in the upcoming large changes, Sunil and I have decided to initiate a full department outside review that will take place in the late Fall or beginning of 2011. This will be a transparent process! Each of you will have an opportunity, indeed, the obligation to speak your minds clearly and suggest improvements. While the reviewers have not been finalized, they

Chairs’ statement continued...

will all be academic leaders in neuroscience who will help us understand what is powering our success, help develop mechanisms for alleviating our deficits, and most important, help us maximize our opportunities. Given the quality of people in our department and our record of success in an adverse financial climate, we have every reason to be optimistic about our abilities to simultaneously change and achieve.

“The world of achievement has always belonged to the optimist” – Harold Wilkins

~ Peter Kalivas, PhD

$1 Million to Support Parkinson’s Disease Research at MUSC

Mr. and Mrs. Charles Barmore of Fair Play, SC have made a gift of $1 M to support Parkinson’s disease (PD) research. Having never even been to campus, the Barmores saw a program on television that highlighted the advances being made in movement disorders at MUSC. They contacted our development office and eventually made a trip to meet our talented team of both clinical and basic science researchers. After a tour of Dr. Lotta Granholm’s laboratory, a round table discussion of the latest advances in research and patient care with Dr. Mark Kindy and Dr. David Bachman, they ended the tour with a presentation by Dr. Vanessa Hinson and Vicky Salak.

Initially interested in making a contribution through their estate plans, the Barmore’s decided upon a current gift in order to provide immediate support for research.

“When we decided that we wanted to donate to PD research we made several calls, one being to MUSC. We were so positively received that we asked to visit the campus. On our visit we were able to meet with researchers and doctors and engage in a wonderful exchange of information. We anticipate further advancements in MUSC’s research and want to be a part of it since I have PD. Advancements in the cure of PD will come only if research funds are provided.” – Charles Barmore

This gift will be stewarded by a committee composed of clinicians and scientists who will determine the use of these funds on a yearly basis. Debbie Bordeau, Director of Development for Neuroscience Institute and the Center on Aging said “This marks an important collaborative fundraising effort that will provide support for both basic science and clinical initiatives.”

Mr. and Mrs. Charles Barmore of Fair Play, SC who recently made a gift of $1 M to support Parkinson’s disease research.
Glioblastoma, Recurrent (1):
Open-label Dose Confirmation and Dosimetry Study of Intrathecal 131I-chTNT-1/b MAbs (Cotara®) for the Treatment of Glioblastoma Multiforme (GBM) at First Relapse
CTO: 101429
Principal Investigator: Kenneth Spicer, MD
Co-Principal Investigators: Sunil J. Patel, MD & CTO: 101429
of Glioblastoma Multiforme (GBM) at First Relapse

Glioblastoma, Recurrent (2):
A Phase III Study of Intraventricular DepoCyt (Orphan Drug Designation 06-2348) in Patients with Recurrent Glioblastoma
CTO: 101254
Principal Investigator: Bruce Frankel, MD
Tel: 843-792-2423
E-mail: frankel@musc.edu
Study Coordinator: John Keller
Tel: 843-792-1286
Email: kellej@musc.edu
Coordination Site: Clinical Trials Office (Hollings Cancer Center)
Status: Active

Anaplastic Glioma, Adjuvant (1): *
RTOG EORTC 0834/26053 22054, “Phase III Trial on concurrent and adjuvant temozolomide chemotherapy in Non-1p/19q deleted anaplastic glioma.”
CTO: 101450
Principal Investigator: Pierre Giglio, MD
Tel: 843-792-6592
E-mail: giglio@musc.edu
Study Coordinator: John Keller
Tel: 843-792-1286
Email: kellej@musc.edu
Coordination Site: Clinical Trials Office (Hollings Cancer Center)
Status: Active

Anaplastic Glioma, Adjuvant (2):
A Phase III Study of Intraventricular DepoCyt (Orphan Drug Designation 06-2348) in Patients with Recurrent Glioblastoma
CTO: 101254
Principal Investigator: Bruce Frankel, MD
Tel: 843-792-2423
E-mail: frankel@musc.edu
Study Coordinator: John Keller
Tel: 843-792-1286
Email: kellej@musc.edu
Coordination Site: Clinical Trials Office (Hollings Cancer Center)
Status: Active

Low Grade Glioma, Progressive:
ECOG E3F05, “Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas”
CTO: 101399
Principal Investigator: Pierre Giglio, MD
Tel: 843-792-6592
E-mail: giglio@musc.edu
Study Coordinator: John Keller
Tel: 843-792-1286
Email: kellej@musc.edu
Coordination Site: Clinical Trials Office (Hollings Cancer Center)
Status: Active

Meningioma, Adjuvant:
Phase II Trial of observation for low-risk meningiomas and of radiotherapy for intermediate and high-risk meningiomas
CTO: 101382
Principal Investigator: Pierre Giglio, MD
Tel: 843-792-6592
E-mail: giglio@musc.edu
Study Coordinator: John Keller
Tel: 843-792-1286
Email: kellej@musc.edu
Coordination Site: Clinical Trials Office (Hollings Cancer Center)
Status: Active

For BTTC-08-01
This much anticipated study for adjuvant therapy glioblastoma examines the potential of improved outcome for poor prognosis tumors (i.e. tumors that are lacking MGMT promoter methylation). The exciting combination of bevacizumab, a vascular endothelial growth factor A (VEGF-A) monoclonal humanized antibody, and erlotinib, an EGFR blocker administered together after standard therapy with surgery and chemoradiation therapy focuses on two very important targets in glioblastoma. The study is made possible by membership of our Brain & Spine Tumor Program in the Brain Tumor Trials Collaborative (BTTC) a multicenter collaborative of academic centers with comprehensive neuron-oncology programs.

For RTOG EORTC – 0834/26053 22054
This multi-center, multinational trial is investigating the most important current question in anaplastic (Grade III) gliomas: does adjuvant and/ or concurrent chemotherapy provide benefit beyond that afforded by radiation therapy alone? The current variability in the care of these patients in the adjuvant setting testifies to the importance of the information that will be gleaned from this study. Patient randomization will be to four arms: Radiation therapy alone, radiotherapy with concurrent chemotherapy, radiotherapy with adjuvant chemotherapy and radiotherapy with both concurrent and adjuvant chemotherapy.

Information on Newly Activated Trials

* For BTTC-08-01
This much anticipated study for adjuvant therapy glioblastoma examines the potential of improved outcome for poor prognosis tumors (i.e. tumors that are lacking MGMT promoter methylation). The exciting combination of bevacizumab, a vascular endothelial growth factor A (VEGF-A) monoclonal humanized antibody, and erlotinib, an EGFR blocker administered together after standard therapy with surgery and chemoradiation therapy focuses on two very important targets in glioblastoma. The study is made possible by membership of our Brain & Spine Tumor Program in the Brain Tumor Trials Collaborative (BTTC) a multicenter collaborative of academic centers with comprehensive neuron-oncology programs.

* For RTOG EORTC – 0834/26053 22054
This multi-center, multinational trial is investigating the most important current question in anaplastic (Grade III) gliomas: does adjuvant and/ or concurrent chemotherapy provide benefit beyond that afforded by radiation therapy alone? The current variability in the care of these patients in the adjuvant setting testifies to the importance of the information that will be gleaned from this study. Patient randomization will be to four arms: Radiation therapy alone, radiotherapy with concurrent chemotherapy, radiotherapy with adjuvant chemotherapy and radiotherapy with both concurrent and adjuvant chemotherapy.
### Neurosciences: Fourth Quarter Grants Awarded

<table>
<thead>
<tr>
<th>PI Full Name</th>
<th>Main Title</th>
<th>Agency 1</th>
<th>Agency 2</th>
<th>Total Direct</th>
<th>Total Indirect</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aston-Jones, Gary</td>
<td>Role of Extended Amygdala in Opiate and Cocaine Abuse</td>
<td>NIH/NIDA</td>
<td></td>
<td>297,000</td>
<td>141,075</td>
<td>438,075</td>
</tr>
<tr>
<td>Bhat, Narayan R.</td>
<td>Atherogenic Induction of Neuroinflammation</td>
<td>NIH/NINDS</td>
<td></td>
<td>124,987</td>
<td>59,369</td>
<td>184,356</td>
</tr>
<tr>
<td>Chimowitz, Marc</td>
<td>SAMMPRIS(Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis)</td>
<td>NIH/NINDS</td>
<td></td>
<td>3,797,173</td>
<td>402,827</td>
<td>4,200,000</td>
</tr>
<tr>
<td>Chandler, L. Judson</td>
<td>Actin Dynamics and Spine Remodeling in Ethanol-Induced Plasticity</td>
<td>NIH/NIAAA</td>
<td></td>
<td>235,125</td>
<td>111,684</td>
<td>346,809</td>
</tr>
<tr>
<td>Flynn Longmire, Crystal</td>
<td>Observational Study of Long-Term (18 Month) Cognitive Outcomes in Healthy Volunteers, Patients with Mild Cognitive Impairment (MCI) and Patients with Alzheimer’s Disease (AD) Who have Previously had PET Imaging with Florpiramine F 18 (F-AV-45) Injection</td>
<td>Avid Radio-pharmaceuticals, Inc.</td>
<td></td>
<td>97,800</td>
<td>24,450</td>
<td>122,250</td>
</tr>
<tr>
<td>Halford, Jonathan</td>
<td>An Open-Label, Pilot Study to Assess the Safety of Oral Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects with Idiopathic Generalized Epilepsy (SP9961)</td>
<td>Schwarz Pharma AG</td>
<td></td>
<td>85,154</td>
<td>20,538</td>
<td>105,692</td>
</tr>
<tr>
<td>Halford, Jonathan</td>
<td>An Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated with Long-Term Oral Lacosamide for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects with Idiopathic Generalized Epilepsy (SP962)</td>
<td>Schwarz Pharma AG</td>
<td></td>
<td>59,768</td>
<td>14,192</td>
<td>73,960</td>
</tr>
<tr>
<td>Halford, Jonathan</td>
<td>Supplemental OLRT Data Collection</td>
<td>Optima Neuroscience, Inc.</td>
<td></td>
<td>36,000</td>
<td>9,000</td>
<td>45,000</td>
</tr>
<tr>
<td>Kalivas, Peter</td>
<td>Glutamate and Craving for Cocaine</td>
<td>NIH/NIDA</td>
<td></td>
<td>212,500</td>
<td>100,938</td>
<td>313,438</td>
</tr>
<tr>
<td>Kalivas, Peter</td>
<td>Neurobiology of Addiction Center</td>
<td>NIH/NIDA</td>
<td></td>
<td>861,670</td>
<td>395,332</td>
<td>1,257,202</td>
</tr>
</tbody>
</table>
Grants Continued...

<table>
<thead>
<tr>
<th>Name</th>
<th>Project Description</th>
<th>Institution</th>
<th>NIH/NINDS</th>
<th>Match Total</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kindy, Mark S.</td>
<td>Complement and Traumatic Brain Injury</td>
<td>VAMC</td>
<td>235,200</td>
<td>0</td>
<td>235,200</td>
</tr>
<tr>
<td>Lackland, Daniel T.</td>
<td>Etiology of Geographic and Racial Differences in Stroke</td>
<td>Univ. of Alabama, Birmingham</td>
<td>52,647</td>
<td>23,507</td>
<td>76,154</td>
</tr>
<tr>
<td>McGinty, Jacqueline F.</td>
<td>Psychostimulant Effects on Striatal Signaling</td>
<td>NIH/NIDA</td>
<td>194,040</td>
<td>89,258</td>
<td>283,298</td>
</tr>
<tr>
<td>Mintzer, Jacobo</td>
<td>A Randomized, Double-Blind, Placebo-Controlled, Two Dose-Arm, Add-On Study</td>
<td>Univ. of California, San Diego</td>
<td>4,800</td>
<td>1,200</td>
<td>6,000</td>
</tr>
<tr>
<td>Mintzer, Jacobo</td>
<td>A Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study Evaluating the</td>
<td>Univ. of California, San Diego</td>
<td>28,903</td>
<td>7,226</td>
<td>36,129</td>
</tr>
<tr>
<td>Mintzer, Jacobo</td>
<td>Amyloid Imaging, VMCI, and Analysis for ADNI</td>
<td>Univ. of California, San Diego</td>
<td>56,200</td>
<td>14,050</td>
<td>70,250</td>
</tr>
<tr>
<td>Papamitsakis, Nikolaos I. H.</td>
<td>CD-0125: Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke</td>
<td>Coaxia, Inc.</td>
<td>21,814</td>
<td>5,453</td>
<td>27,267</td>
</tr>
<tr>
<td>Reichel, Carmela</td>
<td>Reversal of Methamphetamine Induced Cognitive Deficits and mGlu Receptors</td>
<td>NIH/NIDA</td>
<td>47,608</td>
<td>0</td>
<td>47,608</td>
</tr>
<tr>
<td>Ramamoorthy, Samantha</td>
<td>Serotonin Transporter Phosphorylation</td>
<td>NIH/NIMH</td>
<td>212,500</td>
<td>97,750</td>
<td>310,250</td>
</tr>
<tr>
<td>Turner, Raymond</td>
<td>Micrus Physician Training Program</td>
<td>Micrus Endovascular Corp.</td>
<td>11,716</td>
<td>3,691</td>
<td>15,407</td>
</tr>
<tr>
<td>Turner, Raymond</td>
<td>Supplemental OLRT Data Collection</td>
<td>MindFrame, Inc.</td>
<td>36,000</td>
<td>9,000</td>
<td>45,000</td>
</tr>
<tr>
<td>Turner, Raymond</td>
<td>Aneurysm Histology Registry</td>
<td>MicroVention, Inc.</td>
<td>104,800</td>
<td>26,200</td>
<td>131,000</td>
</tr>
<tr>
<td>Walker, Aljoeson</td>
<td>Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established</td>
<td>Age Medical Corp.</td>
<td>72,882</td>
<td>18,221</td>
<td>91,103</td>
</tr>
</tbody>
</table>
To read this article visit the following link: http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0404.2010.01397.x/full

Program Begins Between MUSC and France
The first year of the exchange program between the French University of Poitiers and MUSC started off strong.

Joelle Roche, Ph.D. was instrumental in arranging for the first two students, Charlene Le Gal and Anais Dinh, to come. The students spent three months, May through July, in the laboratories of Naren L. Banik, Ph.D., neurosciences, Harry Drabkin, M.D., hematology, and Robert Gemmill, Ph.D. oncology.

Supriti Samanta Ray, Ph.D., mentored LeGal and Roche mentored Dinh. Both students completed their respective projects, which will enable them to earn credits for their first year of the masters program in the University of Poitiers. Le Gal also actively participated in other ongoing projects in the lab and contributed towards compiling a review with Varduali Knaryan, Ph.D.

Dr. Ray said it was a great start for the exchange program for the mutual benefit of both institutions, and it helps to promote collaboration in teaching and research.

NRSA Postdoc Awarded
Matt Riedy, a postdoc in the neurosciences department, received a new NRSA (National Research Service Award). postdoc award.

National Research Service Awards are named after Dr. Ruth L. Kirschstein. "Aside from Dr. Kirschstein’s scientific accomplishments in polio vaccine development and becoming the first woman director of an NIH Institute, she was a champion of research training and a strong advocate for the inclusion of underrepresented individuals in the scientific workforce."

More on Dr. Kirschstein’s life can be found at: http://www.nigms.nih.gov/Training/Ruth-Kirschstein.

To read this article please visit the Neurology Residency News website.

Deep Brain Stimulation Case
This is our second (deep brain stimulation to treat obsessive compulsive disorder) case this year. As per Medtronic, we remain in the lead in providing this therapy for OCD in the nation. I am currently working up a possible 3rd case and will keep you posted.

- Dr. Ziad Nahas

Clinical Neurophysiology Fellowship
Neal Maru, M.D. and Leo Bonilha, M.D., Ph.D. have been selected as fellows in clinical neurophysiology at MUSC for the 2011-2012 academic year. They are currently senior residents in the neurology residency program. Dr. Maru is an alumnus of the MUSC College of Medicine, Class of 2007, and Dr. Bonilha holds M.D. and Ph.D. degrees from Universidade Estadual de Campinas in Sao Paulo.

Neurology Residency News
Brody Henkel, M.D., who just started the Clinical Neurophysiology fellowship, achieved the highest score in the residency program for the AANEM exam, a national test offered annually to residents to assess their knowledge of peripheral clinical neurophysiology. Dr. Henkel will receive a cash award for his achievement.

Neal Maru, M.D.
Leo Bonilha, M.D., Ph.D.
Brody Henkel, M.D.
The Classic Ketogenic Diet
Meal Preparation Training

Lauren Whiteside, RD, LD
Nurse Health Services
Medical University of South Carolina
2010

Yes Campaign
Thank you for your generous gifts to this year’s YES Campaign. Neurosciences funds received more than $9,000!

Haven’t made your YES Campaign gift yet? Make yours count now for 2011. Designate your gift to any Neurosciences fund…

•ALS Clinic Fund
•Alzheimer’s Research & Clinical Program
•Brain Tumor Research
•Center on Aging
•Cerebral Aneurysm Research
•Murray Center for Research in Parkinson’s Disease and Related Disorders
•Neurology Support
•Neuroscience Educational Fund
•Multiple Sclerosis
•Neurosurgery
•Perot Endowed Chair in Spinal Cord Injury
•REACH Fund: Remote Evaluation of Acute Ischemic Stroke
•REEF: Research and Education in Epilepsy Fund
•Senior Mentor Program
•Stroke Service Educational Fund
•Carroll A. Campbell Neurology Laboratory

To make your gift online, go to:
https://giving.musc.edu/yes/

For questions please contact:
Whitney McLuen
Employee Campaign Coordinator
792-1973
mcluen@musc.edu

REACH Update:
Expanding Specialty Care

In 2008, the REACH MUSC Telestroke Program was established to extend stroke care beyond MUSC (NeuroNews, May 2010 issue). This program has experienced rapid growth since its inception; expecting to offer expert consultations to over a dozen communities/rural hospital representing approximately 2,000 licensed beds by the end of 2010. However, this novel method of patient care delivery is not just for stroke anymore.

The expanded REACH MUSC telemedicine network will facilitate care in other specialty areas, beginning with sepsis and trauma. Funded by the National Institute of Health’s Center for Minority Health and Disparities (RC1MD004405-01), Critical Care Excellence in Sepsis and Trauma (CREST) has partnered with REACH “to improve outcomes for sepsis & trauma through telemedicine consults and provider education.”

According to CREST principal investigators, Dee Ford, MD (Pulmonary/Critical Care Medicine) and Samir Fakhry, MD (Department of Surgery):

Sepsis kills 250,000 per year and accounts for 40% of ICU costs or over $17 billion annually.

Trauma kills 150,000 Americans, is the #1 killer from age 1-44 years, and costs over $450 billion annually.

THE 5 W’s of CREST:

What? A federally funded research grant using transformative approaches to enhance rural health

Who? Patients and providers confronting sepsis and trauma.

Where? Rural S.C. Emergency Departments and the Medical University of South Carolina

When? September 2009 through September 2011

Why? Onsite specialists for sepsis and trauma will remain in limited supply in rural communities. Telemedicine allows rural patients access to these specialists remotely.

Building on experience garnered in telestroke, CREST will be the first non-stroke program at MUSC to utilize the REACH internet-based telemedicine platform to bring specialty services to the rural/underserved communities of S.C. However, this expansion will not be the last.

Progress is currently underway to integrate REACH with the existing South Carolina Department of Mental Health and The Duke Endowment funded (DMH/Duke) Telepsychiatry Project. This evolution will allow hospitals to utilize one integrated device to serve their multiple telemedicine needs.

Other innovations are on the horizon, including various tele-research initiatives and a rapid imaging opportunity but that is another story…

-Update from Lynn Brown, MBA

Bob Weldon- A story of perseverance

Bob Weldon, a patient of MUSC’s brain tumor team has recently had his 7th cranieotomy procedure. Mr. Weldon, who has been in the hospital for a series of surgical interventions since 1999, is a role model for other patients and staff with his positive attitude. “Just had my 7th cranie to remove 2 recurring (meningiomas). Surgery Monday and came home yesterday! Feeling good. Have to go back next week for follow up & get staples out. (No big deal)!”, “Dr. Patel, who stopped in the am after my surgery by Dr.Vandergrift, said I may set here in 2003 with Dr. “Buddy” Jenrette, Radiation-oncologist, who was the best doctor I could have had to a great, caring medical center. Since then I have been seeing great Neuro-oncologists, Dr. Pierre Gigia, Neurosurgeons, Drs. Patel & Vandergrift, and great nursing/support staff & other Docs. They are so easy to contact and very responsive, and on top of all the latest procedures and research.”
Gold Plus Awarded to the Stroke Program

The Medical University of South Carolina has been recognized this past year for your quality care in CAD, Heart Failure and Stroke through the Get with the Guidelines (GWTG) program.

MUSC is now being listed in the Best Hospital issue of U.S. News and World Report as a Triple Gold Award Recipient.

GWTG-Stroke:  Gold Plus
GWTG-Heart Failure:  Gold Plus
GWTG-CAD:  Gold

MUSC is one of 814 hospitals listed in the Best Hospital issue of the U.S. News and World Report that is now on newsstands.

Madaktari Featured in Post and Courier

The Post and Courier recently published a series of articles on the wonderful work that Dr. Ellegala has begun in Tanzania. These articles describe how Dr. Ellegala has acted upon his vision to create a self-sustaining change in health care delivery in that country that will serve as an example for the entire developing world.

To read the articles please visit the Post and Courier at:


MUSC is also one of only 33 hospitals nationwide who are recognized in the Triple Gold category.

MUSC will be invited to the award ceremonies at Scientific Sessions and the International Stroke Conference this year, where the stroke team will be recognized.

MUSC is also listed on the American Heart Association’s website.

http://www.heart.org/idc/groups/heart-public/@wcm/@private/@hcm/@gwtg/documents/downloadable/ucm_311045.pdf

<http://www.heart.org/idc/groups/heart-public/@wcm/@private/@hcm/@gwtg/documents/downloadable/ucm_311045.pdf>

Graduate Student Elected

Graduate student Zackary Cope from the department of Neurosciences was elected Vice-President of the Graduate Student Association for 2010-2011.

The GSA Senate acts as the representative council for the College of Graduate Studies. The goal of the GSA is to promote graduate student involvement in university affairs by initiating dialogue between students and faculty while encouraging student interest and involvement.

For additional information, please visit http://www.musc.edu/gsa.

MUSC Branding Campaign

On August 16th, MUSC launched a new communications campaign statewide. The campaign focuses on how you and MUSC:

- Are changing what’s possible for the health of our patients through excellent care, cutting-edge research and education
- Are rapidly taking our place among the nation’s most respected academic medical centers

The campaign will include:

- TV, Print, radio and online advertising
- A video focusing on how MUSC is changing what’s possible

"Initially, we will feature three specific areas (Heart and Vascular Center, Hollings Cancer Center, and Neurosciences) because they represent a high proportion of the patients who we serve. As the state’s only academic medical center, we have a responsibility to address these prevalent conditions. Patients with these diseases need to know we can provide innovative and cutting-edge care right here, and right now. If successful, we will grow these services and bring more resources to the institution. In other words, we can care for more patients, improve the health of our state, and improve the resources of the University, but only if the public understands the great strengths that we offer." - Raymond S. Greenberg, M.D., Ph.D.

To learn more about the campaign visit:

http://www.musc.edu/ourmusc/home.html

Neurosciences Physician Speaks at Summit

Neurosciences faculty member Christine Holmstedt spoke at the National Women and Girls Summit this past July. Several MUSC physicians were asked to speak on a Women’s Health Panel on Saturday the 17th. Marian Taylor spoke on cardiovascular health and coronary artery disease prevention, Christine Holmstedt spoke on stroke prevention, Barbara Wright-Downs spoke on diet modification and diabetes prevention, and Diane Kamen spoke on lupus. There was a great turnout, and the women from the community seemed to really appreciate having the MUSC doctors there to speak and answer questions.

Neurosciences Physician

Christine Holmstedt

MUSC Branding Campaign

On August 16th, MUSC launched a new communications campaign statewide. The campaign focuses on how you and MUSC:

- Are changing what’s possible for the health of our patients through excellent care, cutting-edge research and education
- Are rapidly taking our place among the nation’s most respected academic medical centers

The campaign will include:

- TV, Print, radio and online advertising
- A video focusing on how MUSC is changing what’s possible

"Initially, we will feature three specific areas (Heart and Vascular Center, Hollings Cancer Center, and Neurosciences) because they represent a high proportion of the patients who we serve. As the state’s only academic medical center, we have a responsibility to address these prevalent conditions. Patients with these diseases need to know we can provide innovative and cutting-edge care right here, and right now. If successful, we will grow these services and bring more resources to the institution. In other words, we can care for more patients, improve the health of our state, and improve the resources of the University, but only if the public understands the great strengths that we offer." - Raymond S. Greenberg, M.D., Ph.D.

To learn more about the campaign visit:

http://www.musc.edu/ourmusc/home.html
Physician Participates in Target Championships

Dr. Nancy Tsai, MUSC neurologist, just recently returned from participating in the World Field Archery Championships as part of Team USA. The event was held in Visegrad, Hungary in July, where she qualified 19th with her score of 501 for recurve women. She also competed in the 125th US National Target Championship where she ranked 26th with a total score of 1626 in the National Target Results.

For more information view the results at USA archery events:
http://usarchery.org/events/1302
or

Sharon Vendrick Retires

Sharon Vendrick, MUSC Neuroscience Clinic Nurse Manager retired Friday July 23, 2010 after 31 years of service. Thank you Sharon for all of your hard work and dedication.

Deborah Adams, RN, BSN, MA will be taking over Sharon’s role as the new Neuroscience Clinic Nurse Manager. She will assume her new role on August 15.

Ms. Adams received her BSN from St. Louis University and her MA in management and leadership from Webster University. She has many years experience as a nurse and multiple years experience as a nurse manager within Ambulatory Care at MUSC at the Family Medicine Clinic and the Hollings Cancer Center. We are excited to have her on our team.

Sharon Vendrick

Employee Update

Goodbye and Good Luck

Amy Duppsstadt-Delambo, Clinical Instructor
David Griesemer, MD
Paola Tuminello, MD
Ian Johnson, MD
Nikolaos Papanitakis, MD
Nada Abou-Fayssal, MD
Alyssia Barnes, Admin Asst
Tim Whitfield, GS
Joseph Mingola, PD
Pouya Tahsili-Fahadan, PD
Amanda Andre, Program Assistant
Stephanie Warth, Program Asst
Sven Kroener, Res Asst Prof
Kathy Bradbury, Research Nurse II
Cathleen Miret, RNII
Ilan Sondheimer, RSI
Samantha Donald, RSI-Study Coord
Sharon Vendrick, Clinical Nurse Manager

I am grateful to many of you for your help over the years and to others for your outstanding work as outstanding colleagues. For those who wish to keep in touch, here is my new contact information:

Office: Division of Pediatric Neurology Floating Hospital for Children at Tufts Medical Center
800 Washington Street, Box 330 Boston, MA 02111
dgriesemer@tuftsmedicalcenter.org
617-636-5356 (division office)

- David Griesemer

Welcome New Employees

Jean Dangerfield, Admin Asst in Neurology
Gonzalo Revuelt, D.O. July 15 Movement Disorders Program
Gabriel Martz, M.D. Aug 1 Epilepsy program
Mimi Sohn, M.D., M.S. Sept 1 Inpatient Service/General Neurology
Christine Holmstedt, D.O. July 1 Stroke program
Gloria Moran, Admin Spec. II (PT)
Sonny King, Info. Resource Consultant II
Manuel Levy, Post Doc
Justin Gass, Post Doc
Meghan Steiner, Prog. Asst.
Michael Thomas, Prog. Coord. I
Judy Luden, Prog. Coord. II
Caroline Mason, Public Info. Coord.
Jennifer Garry, RNII
Ashley King, RSI
Sam Donald, RSI (Study Coordinator)
Cheryl Mazelli, RSI
Subhajit Dasgupta, Staff Scientist
Hanaa El Sayed, Staff Scientist
Emily Williams, Student/Other
Robert Relic, PA Neurosciences
Steve Giles, PA Neurosurgery
Deborah Adams, Clinic Nurse Manager
Michele DeCandido, TRU Neuro-Onc Clinical Trials Nurse Coordinator
Rebecca Lehman, MD Pediatric Neurology – July 1
Alyssa Cogdill, PNP, Pediatric Neurology – July 1

Sharon Vendrick

Farewell Letters from Drs. Tuminello and Griesemer

Hi everybody,

As much as this saddens me I want to confirm the “rumor” that I am leaving MUSC on September 3. I have been in MUSC since 1992 (with the exception of 4 years in private practice and then came back here). I was given the opportunity of a lifetime in Jacksonville University as medical director of their sleep lab. It has been a dream I had for so long to start a fellowship program in sleep medicine, this was the chance to fulfill it and I just could not say no. I will be missing all of you, you are such a great group of people to work with. There will always be a special place in my heart for MUSC. Thank you for all.

- Paola Tuminello

Welcome New Employees

Jean Dangerfield, Admin Asst in Neurology
Gonzalo Revuelt, D.O. July 15 Movement Disorders Program
Gabriel Martz, M.D. Aug 1 Epilepsy program
Mimi Sohn, M.D., M.S. Sept 1 Inpatient Service/General Neurology
Christine Holmstedt, D.O. July 1 Stroke program
Gloria Moran, Admin Spec. II (PT)
Sonny King, Info. Resource Consultant II
Manuel Levy, Post Doc
Justin Gass, Post Doc
Meghan Steiner, Prog. Asst.
Michael Thomas, Prog. Coord. I
Judy Luden, Prog. Coord. II
Caroline Mason, Public Info. Coord.
Jennifer Garry, RNII
Ashley King, RSI
Sam Donald, RSI (Study Coordinator)
Cheryl Mazelli, RSI
Subhajit Dasgupta, Staff Scientist
Hanaa El Sayed, Staff Scientist
Emily Williams, Student/Other
Robert Relic, PA Neurosciences
Steve Giles, PA Neurosurgery
Deborah Adams, Clinic Nurse Manager
Michele DeCandido, TRU Neuro-Onc Clinical Trials Nurse Coordinator
Rebecca Lehman, MD Pediatric Neurology – July 1
Alyssa Cogdill, PNP, Pediatric Neurology – July 1
NEI-funded Positions
Molecular and Cell Biology of AMD

Postdoctoral fellow(s) - Recent Ph.D. or equivalent, with experience in molecular biology, protein chemistry, immunohistochemistry and cell biology preferred. Experience with complement biology and/or animal models of AMD will be advantageous.

Research Assistant – Recent B.S. or equivalent with skills in electrophysiology or microscopy preferred. Will also be responsible for maintaining animal colonies.

Our research focuses on identifying complement-mediated pathology in models of AMD (RPE cultures and mouse models). The project aim to answer the following essential questions: 1) which complement pathway is involved in RPE damage and CNV in dry and wet AMD; 2) is complement produced locally within the eye or is it recruited from the circulation; 3) do oxidative stress and complement act synergistically in the disease process; 4) does complement activation control secretion of factors contributing to pathology; and most importantly, 5) can we target the complement cascade therapeutically.

Applicants should send curriculum vitae, a cover letter, and names of three references to:

Bärbel (Barb) Rohrer, Ph.D., Department of Ophthalmology, Storm Eye Institute, 167 Ashley Ave, Rm 511, Charleston, SC 29425; email rohrer@musc.edu. Department of Ophthalmology

For a full list of available positions visit: http://academicdepartments.musc.edu/vpfa/hrm/index.htm